Literature DB >> 22223693

Sleeve lobectomy after induction chemoradiotherapy.

Abel Gómez-Caro1, Marc Boada, Noemí Reguart, Nuria Viñolas, Frances Casas, Laureano Molins.   

Abstract

OBJECTIVES: The effect of induction chemoradiotherapy (CRT) on bronchial anastomoses remains uncertain. This prospective study aimed to assess the impact of neoadjuvant CRT on mortality, morbidity and survival following circular sleeve lobectomy (SL).
METHODS: All consecutive patients undergoing SL between June 2005 and December 2010 were prospectively included. Clinico-demographic variables were sex, age, clinical and pathologic TNM staging, comorbidities, pulmonary function, SL type, complications, neoadjuvant CRT and mortality.
RESULTS: Of 79 patients, who underwent SL during this period, 53 (67%) patients were directly assigned to surgery and 26 (33%) patients had pre-induction treatment for N2 pathologically confirmed. Induction treatment (CRT) was based on platinum-based chemotherapy and radiation (range 45-60 Gy). Twenty-one (80%) patients of the CRT group achieved a complete mediastinal pathological response. Mortality occurred in only three cases in the non-CRT [bronchovascular fistula, pulmonary artery thrombosis (reoperation and pneumonectomy and exitus due to pneumonia) and ADRS]. There were no differences with respect to complication rate between the non-CRT and CRT patients (33 versus 37%, P > 0.05), and overall 5-year survival was 69 and 33%, respectively (P = 0.017). Overall survival in the subgroup of CRT patients with mediastinal complete response after induction resulted significantly worse than the non-CRT group (43 versus 69%, P < 0.01). The rate of distant metastases was similar in both groups and only one patient experienced local recurrence.
CONCLUSIONS: Neoadjuvant CRT does not increase surgical morbidity, anastomotic complications or mortality in SL. Complete mediastinal response after induction therapy overcomes a significant independent prognostic factor for better survival. Although SL following induction CRT carries a good prognosis, the long-term results shows significantly lower survival compared with SL without induction CTR. In addition, patients who had complete pathological responses have a better prognosis than non-responders. SL appears to be safe and reliable after neoadjuvant concurrent CRT and can be considered the primary surgical option to save the complications related to pneumonectomy in central tumours.

Entities:  

Mesh:

Year:  2012        PMID: 22223693     DOI: 10.1093/ejcts/ezr184

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Extended-sleeve lobectomy: a technically demanding last-ditch effort in lung sparing surgery for central tumor.

Authors:  Charlotte Cohen; Jean-Philippe Berthet
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  eComment. Should persistent N2/N3 non-small cell lung cancer be treated by surgery?

Authors:  Alessandro Baisi; Federico Raveglia; Matilde De Simone; Ugo Cioffi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-12

3.  Bronchial sleeve resection or pneumonectomy for non-small cell lung cancer: a propensity-matched analysis of long-term results, survival and quality of life.

Authors:  Saana E M Andersson; Ville H S Rauma; Eero I Sihvo; Jari V Räsänen; Ilkka K Ilonen; Jarmo A Salo
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

4.  Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence?

Authors:  Branislav Jeremic; Francesc Casas; Pavol Dubinsky; Antonio Gomez-Caamano; Nikola Cihoric; Gregory Videtic; Miroslav Latinovic
Journal:  J Radiat Res       Date:  2017-05-01       Impact factor: 2.724

Review 5.  Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer.

Authors:  Branislav Jeremić; Francesc Casas; Pavol Dubinsky; Antonio Gomez-Caamano; Nikola Čihorić; Gregory Videtic; Ivan Igrutinovic
Journal:  Front Oncol       Date:  2018-02-20       Impact factor: 6.244

6.  Is sleeve lobectomy safe after induction therapy?-a systematic review and meta-analysis.

Authors:  Louis-Emmanuel Chriqui; Céline Forster; Alban Lovis; Hasna Bouchaab; Thorsten Krueger; Jean Yannis Perentes; Michel Gonzalez
Journal:  J Thorac Dis       Date:  2021-10       Impact factor: 3.005

7.  The outcomes of margin status after sleeve lobectomy for patients of non-small cell lung cancer.

Authors:  Jianghao Ren; Mingyang Zhu; Yuanyuan Xu; Ruijun Liu; Ting Ren; Zhiyi Guo; Jiangbin Ren; Kan Wang; Qiang Tan
Journal:  Thorac Cancer       Date:  2022-05-05       Impact factor: 3.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.